View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 7, 2022

UC San Diego joins NIAID-sponsored trial of Covid-19 booster vaccines

The COVAIL study will assess the safety and immunogenicity of additional doses of prototype and variant vaccines.

The University of California (UC) San Diego in the US has joined a Phase II clinical trial to assess various Covid-19 booster vaccines. 

Named COVAIL, the trial is sponsored by the National Institutes of Health unit National Institute of Allergy and Infectious Diseases (NIAID).

It will analyse whether various regimens of Moderna-manufactured vaccines can boost immune responses in adults who have previously received the initial vaccine series and a first booster vaccine.

COVAIL is led by the Emory Vaccine Center in Atlanta and the University of Rochester Medical Center in New York researchers.

The first regimen is a dose of Moderna’s Spikevax prototype vaccine, mRNA-1273, which is authorised in the US as a booster for adults.

The second regimen is dosing with an investigational vaccine against the Beta variant, mRNA-1273.351 plus another investigational vaccine against the Omicron variant, mRNA-1273.529.

Two vaccinations administered at a gap of two months with each one containing both mRNA-1273.351 and mRNA-1273.529 vaccines is the third regimen. 

Vaccination with the investigational vaccine against the Delta variant, mRNA-1273.617.2 along with mRNA-1273.529 will be analysed as the fourth regimen.

Inoculation with mRNA-1273.529 vaccine and injection comprising Spikevax plus mRNA-1273.529 will be the fifth and sixth regimens, respectively.

The trial will assess the safety and immunogenicity of additional doses of prototype and variant vaccine candidates in trial subjects. 

Furthermore, the innate, cellular and humoral immune responses will be evaluated.

Trial subjects will be analysed for symptoms and adverse events after inoculation. The initial study data is anticipated by August this year.

The study could run for four years and may be extended to enrol 1,500 subjects in the country, UC San Diego noted.

UC San Diego School of Medicine professor Susan Little said: “The emergence of SARS-CoV-2 variants has challenged the efficacy of available preventive vaccines. 

“It’s clear that we need to learn more about how we might adapt vaccines to match circulating variants and expand and optimise immune coverage to existing and emerging variants.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU